These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9721971)

  • 41. Visceral leishmaniasis in patients with AIDS: report of three cases treated with pentavalent antimony and interferon-gamma.
    de Górgolas M; Castrillo JM; Fernández Guerrero ML
    Clin Infect Dis; 1993 Jul; 17(1):56-58. PubMed ID: 8353246
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Visceral leishmaniasis with cutaneous and rectal dissemination due to Leishmania braziliensis in acquired immunodeficiency syndrome (AIDS).
    Hernández DE; Oliver M; Martínez C; Planas G
    Int J Dermatol; 1995 Feb; 34(2):114-5. PubMed ID: 7737768
    [No Abstract]   [Full Text] [Related]  

  • 43. [Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection].
    Santos J; Rivero A; Márquez M
    An Med Interna; 2000 Oct; 17(10):562-3. PubMed ID: 11109659
    [No Abstract]   [Full Text] [Related]  

  • 44. Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients.
    Pérez-Molina JA; López-Vélez R; Montilla P; Guerrero A
    AIDS; 1996 Feb; 10(2):237-8. PubMed ID: 8838721
    [No Abstract]   [Full Text] [Related]  

  • 45. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
    Ali A
    Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liposomal Amphotericin B drug access for the treatment of leishmaniasis in Brazil.
    Mistro S; Rodrigues M; Rosa L; Camargo M; Badaró R
    Trop Med Int Health; 2016 Jun; 21(6):692-3. PubMed ID: 27037644
    [No Abstract]   [Full Text] [Related]  

  • 47. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.
    Lachaud L; Bourgeois N; Plourde M; Leprohon P; Bastien P; Ouellette M
    Clin Infect Dis; 2009 Jan; 48(2):e16-22. PubMed ID: 19093811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The clinical and evolutional characteristics of visceral leishmaniasis in patients with HIV infection].
    Delgado Fernández M; García Ordoñez MA; Martos Pérez F; Reguera Iglesias JM; Jiménez Oñate F; Colmenero Castillo JD
    An Med Interna; 1997 Oct; 14(10):506-10. PubMed ID: 9424140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cutaneous manifestations of visceral leishmaniasis resistant to liposomal amphotericin B in an HIV-positive patient.
    Alsina-Gibert M; López-Lerma I; Martinez-Chamorro E; Herrero-Mateu C
    Arch Dermatol; 2006 Jun; 142(6):787-9. PubMed ID: 16785393
    [No Abstract]   [Full Text] [Related]  

  • 50. Slow clinical improvement after treatment initiation in Leishmania/HIV coinfected patients.
    Souza GF; Biscione F; Greco DB; Rabello A
    Rev Soc Bras Med Trop; 2012; 45(2):147-50. PubMed ID: 22534981
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HIV/AIDS-associated visceral leishmaniasis in patients from an endemic area in Central-west Brazil.
    Alexandrino-de-Oliveira P; Santos-Oliveira JR; Dorval ME; Da-Costa Fd; Pereira GR; da Cunha RV; Paniago AM; Da-Cruz AM
    Mem Inst Oswaldo Cruz; 2010 Aug; 105(5):692-7. PubMed ID: 20835619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Visceral leishmaniasis (Kala-Azar) in transplant recipients: case report and review.
    Berenguer J; Gómez-Campderá F; Padilla B; Rodríguez-Ferrero M; Anaya F; Moreno S; Valderrábano F
    Transplantation; 1998 May; 65(10):1401-4. PubMed ID: 9625028
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenges in HIV and visceral Leishmania co-infection: future research directions.
    Ejara ED; Lynen L; Boelaert M; Van Griensven J
    Trop Med Int Health; 2010 Oct; 15(10):1266-7. PubMed ID: 20723183
    [No Abstract]   [Full Text] [Related]  

  • 54. [Isolated laringeal leishmaniasis and bone marrow culture (reply)].
    Benítez MD; Miranda C; Navarro JM; Morillas F; Martín J; de La Rosa M
    Enferm Infecc Microbiol Clin; 2002 Mar; 20(3):133-4. PubMed ID: 11904090
    [No Abstract]   [Full Text] [Related]  

  • 55. Fatal haemophagocytic syndrome and hepatitis associated with visceral leishmaniasis.
    Mathur P; Samantaray JC; Samanta P
    Indian J Med Microbiol; 2007 Oct; 25(4):416-8. PubMed ID: 18087100
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
    Marques N; Sá R; Coelho F; Oliveira J; Saraiva Da Cunha J; Meliço-Silvestre A
    Scand J Infect Dis; 2008; 40(6-7):523-6. PubMed ID: 18584541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of leishmaniasis in HIV-positive patients.
    Laguna F
    Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():135-42. PubMed ID: 14678640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The irreplaceable image: Acute toxicity in erythroid bone marrow progenitors after antimonial therapy.
    Hernández JA; Navarro JT; Force L
    Haematologica; 2001 Dec; 86(12):1319. PubMed ID: 11726328
    [No Abstract]   [Full Text] [Related]  

  • 59. [Nephrotic syndrome and acute pancreatitis related to glucantime administration].
    Valencia ME; Laguna F; González Lahoz J
    An Med Interna; 2000 Jan; 17(1):54. PubMed ID: 10730416
    [No Abstract]   [Full Text] [Related]  

  • 60. Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases.
    Lopez Dupla M; Gil Aguado A; Lavilla Uriol P; Pintado Garcia V; Valencia Ortega E; Martinez Martinez P; Garcia-Puig J
    J Antimicrob Chemother; 1993 Oct; 32(4):657-9. PubMed ID: 8288512
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.